Prognostic value of peripheral blood inflammation-based markers in metastatic pancreatic cancer

doi:10.3969/j.issn.1006-7795.2022.02.023

Abstract

Abstract: Objective To evaluate significance of the inflammation-based prognostic markers, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), albumin (ALB) and combined inflammation-based markers in metastatic pancreatic cancer. Methods The clinical data of 50 patients with metastatic pancreatic cancer admitted to VIP-Ⅱ Department of Peking University Cancer Hospital from July 2012 to October 2020 were collected retrospectively. Receiver operating characteristic (ROC) curve analysis were performed to determine the cut-off values of NLR, LMR, PLR and prognostic nutritional index (PNI). The accuracy of the prognostic indicators were evaluated by area under curve(AUC). The prognostic significance of the clinical characteristics and inflammation-based markers were evaluated by univariate and multivariate analysis. Results In 50 patients with metastatic pancreatic cancer, the median overall survival was 7.2 months (95%CI:3.568-10.699). The optimal cut-off of inflammation-based markers were: NLR=4.5 (AUC=0.840, 95%CI:0.732-0.948, P<0.001), PLR=138 (AUC=0.671, 95%CI:0.517-0.826, P=0.038), LMR=4.0 (AUC=0.873, 95% CI:0.770-0.975, P<0.001), ALB=41.5(AUC=0.726, 95% CI:0.582-0.870, P=0.006), respectively. Univariate and multivariate analysis showed that NLR≥4.5 (HR=11.936, 95%CI:4.571-31.169, P<0.001), PLR≥138 (HR=2.246, 95%CI:1.045-4.828, P=0.038), ALB<41.5 g/L (HR=3.214, 95%CI:1.463-7.060, P=0.004) were independent risk factors; LMR≥4 (HR=0.336, 95%CI:0.165-0.687, P=0.003) was an independent protective factor. NLR_ALB, PLR_ALB and LMR_ALB were independent prognostic indicators, and the higher the score, the worse the prognosis. Conclusion Peripheral blood inflammation-based marker NLR, LMR, PLR and ALB can be used as prognostic indicators for metastatic pancreatic cancer, the combined inflammation-based markers will promote simple and rapid prognosis assessments and has a certain clinical application prospect.

Key words: pancreatic neoplasms, inflammation-based markers, prognosis

CLC Number:

R735.9

Sun Jing, Shi Youwu, Jia Jun, Yang Ying, Sun Zhiwei, Du Feng, Yu Jing, Xiao Yanjie, Zhang Xiaodong. Prognostic value of peripheral blood inflammation-based markers in metastatic pancreatic cancer[J]. Journal of Capital Medical University, 2022, 43(2): 299-304.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.02.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I2/299

References

[1] Grossberg A J, Chu L C, Deig C R, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma[J]. CA Cancer J Clin, 2020, 70(5): 375-403.
[2] Shirai Y, Shiba H, Sakamoto T, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection[J]. Surgery, 2015, 158(2): 360-365.
[3] Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer[J]. Br J Cancer, 2013, 109(2): 416-421.
[4] Lee B M, Chung S Y, Chang J S, et al. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy[J]. Gut Liver, 2018, 12(3): 342-352.
[5] Zhou Y P, Cheng S J, Fathy A H, et al. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies[J]. Onco Targets Ther, 2018, 11: 1899-1908.
[6] Hu R J, Ma J Y, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis[J]. Clin Chim Acta, 2018, 481: 142-146.
[7] Zhou Y P, Wei Q, Fan J S, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients[J]. Clin Chim Acta, 2018, 479: 181-189.
[8] Nakano Y, Kitago M, Shinoda M, et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study[J]. Cancer Med, 2017, 6(10): 2278-2286.
[9] Alagappan M, Pollom E L, Von Eyben R, et al. Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT[J]. Am J Clin Oncol, 2018, 41(3): 242-247.
[10] Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer[J]. Pancreatology, 2019, 19(5): 722-728.
[11] Lebenthal J M, Zheng J T, Glare P A, et al. Prognostic value of the memorial Sloan Kettering prognostic score in metastatic pancreatic adenocarcinoma[J]. Cancer, 2021, 127(10): 1568-1575.
[12] Le N, Sund M, Vinci A, et al. Prognostic and predictive markers in pancreatic adenocarcinoma[J]. Dig Liver Dis, 2016, 48(3): 223-230.
[13] Kays J K, Shahda S, Stanley M, et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer[J]. J Cachexia Sarcopenia Muscle, 2018, 9(4): 673-684.
[14] Bachmann J, Heiligensetzer M, Krakowski-Roosen H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer[J]. J Gastrointest Surg, 2008, 12(7): 1193-1201.
[15] Maisey N R, Norman A R, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials[J]. Br J Cancer, 2005, 93(7): 740-743.
[16] Saad E D, Machado M C, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine[J]. Int J Gastrointest Cancer, 2002, 32(1): 35-41.
[17] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?[J]. Lancet, 2001, 357(9255): 539-545.
[18] Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[19] Diakos C I, Charles K A, McMillan D C, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11): e493-e503.
[20] Lecot P, Sarabi M, Pereira Abrantes M, et al. Neutrophil heterogeneity in cancer: from biology to therapies[J]. Front Immunol, 2019, 10: 2155.
[21] Templeton A J, McNamara M G, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(6): dju124.
[22] Oh D, Pyo J S, Son B K. Prognostic roles of inflammatory markers in pancreatic cancer: comparison between the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio[J]. Gastroenterol Res Pract, 2018, 2018: 9745601.
[23] Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients[J]. Int J Mol Sci, 2017, 18(4): 730.
[24] Nakamura Y, Watanabe R, Katagiri M, et al. Neutrophil/lymphocyte ratio has a prognostic value for patients with terminal cancer[J]. World J Surg Oncol, 2016, 14: 148.